Equillium, Inc. (NASDAQ:EQ) Short Interest Up 22.7% in December

Equillium, Inc. (NASDAQ:EQ - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 944,698 shares, an increase of 22.7% from the November 30th total of 770,137 shares. Based on an average daily volume of 512,122 shares, the short-interest ratio is currently 1.8 days. Currently, 2.2% of the shares of the company are short sold. Currently, 2.2% of the shares of the company are short sold. Based on an average daily volume of 512,122 shares, the short-interest ratio is currently 1.8 days.Equillium Price PerformanceThe Top 3 Investment Themes That Will Dominate 2026Shares of Equillium stock remained flat at $1.55 during trading hours on Wednesday. The stock had a trading volume of 535,719 shares, compared to its average volume of 964,886. The stock has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.07. Equillium has a fifty-two week low of $0.27 and a fifty-two week high of $2.35. Equillium (NASDAQ:EQ - Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. On average, equities analysts expect that Equillium will post 0.14 earnings per share for the current year. Insiders Place Their BetsTap Into 2026 AI Infrastructure Gains With This High-Growth ETFIn other news, COO Christine Zedelmayer sold 100,000 shares of the stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $1.50, for a total transaction of $150,000.00. Following the transaction, the chief operating officer directly owned 91,444 shares of the company's stock, valued at $137,166. This represents a 52.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 143,802 shares of company stock worth $205,179. 31.60% of the stock is currently owned by insiders. Hedge Funds Weigh In On EquilliumA number of hedge funds and other institutional investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC bought a new stake in Equillium in the 3rd quarter valued at $7,951,000. Woodline Partners LP bought a new position in shares of Equillium during the 3rd quarter valued at about $5,018,000. Vanguard Group Inc. grew its position in shares of Equillium by 59.4% during the third quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company's stock valued at $1,879,000 after purchasing an additional 489,855 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Equillium in the third quarter worth about $190,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Equillium in the third quarter worth about $178,000. Institutional investors own 27.05% of the company's stock. Analyst Ratings Changes5 AI Infrastructure Stocks Enabling the Next Wave of GrowthSeveral research firms have recently commented on EQ. Weiss Ratings restated a "sell (d-)" rating on shares of Equillium in a research note on Monday. Wall Street Zen raised Equillium from a "sell" rating to a "hold" rating in a research note on Saturday, November 15th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Reduce" and an average target price of $1.00.Check Out Our Latest Analysis on EQEquillium Company Profile (Get Free Report)Equillium, Inc NASDAQ: EQ is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis. Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.See AlsoFive stocks we like better than EquilliumDo not delete, read immediatelyThe Crash Has Already Started (Most Just Don’t See It Yet)ALERT: Drop these 5 stocks before January 2026![No Brainer Gold Play]: “Show me a better investment.”INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Equillium Right Now?Before you consider Equillium, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Equillium wasn't on the list.While Equillium currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here